Long-term administration of galactoside-specific mistletoe lectin in an animal model: No protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine- induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 3, 2000, Pages 125-138

  Kunze, Ekkehard ^a   Schulz, Harald ^a   Adamek, Matthias ^a   Gabius, Hans Joachim ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Agglutinin; Alternative cancer therapies; Cellular immune response; Lectin; Mistletoe; N butyl N (4 hydroxybutyl) nitrosamine; Urinary bladder cancer

Indexed keywords

GALACTOSIDE; LECTIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; LONG TERM EXPOSURE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; VISCUM ALBUM;

EID: 0034053785     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050022     Document Type: Article

References (91)

1. Adamek M (2000) Fehlende Wirkung von Galactosid-spezifischem Mistellektin die N-Butyl-N-(4-hydroxybutyl)-Nitrosamin-induzierte Karzinogenese in der Hamblase der Ratte zu inhibieren und eine substantielle lokale zelluläre Immunantwort hervorzurufen. Medizinische Inauguraldissertation, Göttingen, 2000
2. Ardestani SK, Inserra P, Solkoff D, Watson RR (1999) The role of cytokines and chemokines on tumor progression: a review. Cancer Detect Prevent 23:215-225
3. Berger M, Schmähl D (1983) Studies on the tumor-inhibiting efficacy of Iscador® in experimental animal tumors. J Cancer Res Clin Oncol 105:262-265
4. Beuth J, Ko HL, Gabius H-J, Pulverer G (1991) Influence of treatment with the immunomodulatory effective dose of the β-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In vivo 5:29-32
5. Beuth J, Ko HL, Gabius H-J, Burrichter H, Oette K, Pulverer G (1992) Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Invest 70:658-661
6. Beuth J, Ko HL, Tunggal L, Geisel J, Pulverer G (1993) Vergleichende Untersuchungen zur immunaktiven Wirkung von Galactosid-spezifischem Mistellektin. Reinsubstanz gegen standardisierten Extrakt. Arzneimittelforschung/Drug Res 43:166-169
7. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53-58
8. Burkhard B (1995) Nicht-konventionelle Verfahren in der Onkologie. Gesundheitsökonomische Aspekte. Onkologe 1:583-589
9. Burkhard B (1998) Mistel: Gestaltung eines Mythos. Pharm Ztg 143:1650-1656
10. Büssing A, Stumpf C, Stumpf RT, Wutte H, Schietzel M (1996a) Therapiebegleitende Untersuchung immunologischer Parameter bei Tumorpatienten nach hochdosierter intravenöser Applikation von Viscum album L.-Extrakten. Z Onkol 28:54-59
11. Büssing A, Jurin M, Zarkovic N, Azhari T, Schweizer K (1996b) DNA-stabilisierende Wirkungen von Viscum album L. - Sind Mistelextrakte als Adjuvans während der konventionellen Chemotherapie indiziert? Forsch Komplementärmed 3:244-248
12. Catalona WJ, Ratliff TL (1990) Bacillus Calmette-Guérin and superficial bladder cancer. Surg Annu 22:363-378
13. Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A (1996) Mycobacterium cell wall: an alternative to intravesical bacillus Calmette-Guèrin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156:1189-1193
14. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493-497
15. Dold U, Edler L, Mäurer HC, Müller-Wening D, Sakellariou B, Trendelenburg F, Wagner G (eds) (1991) Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Thieme, Stuttgart New York
16. Drings P, Brittinger G, Gaedicke G, Heimpel H, Hossfeld DK, Huber C, Meurer S, Wannenmacher M, Winkler K (1995) Die moderne Krebsbehandlung. Wissenschaftlich begründete Verfahren und Methoden mit unbewiesener Wirksamkeit. Onkologie 18:158-162
17. Druckrey H, Preussmann R, Ivankovic S, Schmähl D (1967) Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z Krebsforsch 69:103-201
18. Fischer S, Scheffler A, Kabelitz D (1997a) Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44:150-156
19. Fischer S, Scheffler A, Kabelitz D (1997b) Stimulation of the specific immune system by mistletoe extracts. Anticancer Drugs 8 [Suppl 1]:S33-S37
20. Friess H, Berger HG, Kunz J, Funk N, Schilling N, Schilling M, Büchler MW (1996) Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 16:915-920
21. Fujita K (1988) Histological changes caused by intralesional injection of a streptococcal preparation into bladder cancer. Cancer Detect Prevent 11:397-403
22. Gabius H-J (1990) Influence of type of linkage and spacer on the interaction of β-galactoside-binding proteins with immobilized affinity ligands. Anal Biochem 189:91-94
23. Gabius H-J (1997) Concepts of tumor lectinology. Cancer Invest 15:454-464
24. Gabius H-J, Gabius S (1994) Wohin führt die naturwissenschaftliche Forschung über Misteltherapie? Dt Ärztebl 91:A2320-2328
25. Gabius H-J, Gabius S (1996) Mistletoe in oncology: fact or fiction? Onkologie 19:74
26. Gabius H-J, Gabius S (eds) (1997) Glycosciences: status and perspectives. Chapman & Hall, Weinheim London New York
27. Gabius H-J, Gabius S (1998a) Phytotherapeutical immunomodulation as treatment modality in oncology: lessons from research with mistletoe. ACS Symp Ser 691:278-286
28. Gabius S, Gabius H-J (1998b) Mistelextrakte in der Krebstherapie. Pharm Ztg 143:2101-2117
29. Gabius S, Gabius H-J (1999) Immunmodulierende Misteltherapie durch Lektinstandardisierung: ein zweischneidiges Schwert? Versicherungsmedizin 51: 128-136
30. Gabius H-J, Walzel H, Joshi SS, Kruip J, Kojima S, Gerke V, Kratzin H, Gabius S (1992) The immunomodulatory galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding and impact on intracellular biosignaling of monocytic leukemia cells. Anticancer Res 12:669-676
31. Gabius H-J, Gabius S, Joshi SS, Koch B, Schröder M, Manzke WM, Westerhausen M (1994) From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 60:2-7
32. Gabius H-J, Kayser K, Gabius S (1995) Protein-Zucker-Erkennung. Grundlagen und medizinische Anwendung am Beispiel der Tumorlektinologie. Naturwissenschaften 82:533-543
33. Gabius H-J, André S, Kaltner H, Siebert H-C, Lieth C-W von der, Gabius S (1996) Mythos Mistel - Anspruch, Wirklichkeit und prüfbare Perspektive. Z Ärztl Fortbild 90:103-110
34. Gabius S, Joshi SS, Kayser K, Gabius H-J (1992) The galactoside-specific lectin from mistletoe as biological response modifier. Int J Oncol 1:705-708
35. Gupta D, Kaltner H, Dong X, Gabius H-J, Brewer C-F (1996) Comparative crosslinking activities of lactose-specific plant and animal lectins and a natural lactose-binding immunoglobulin G fraction from human serum with asialofetuin. Glycobiology 6:843-849
36. Hagenah W, Dörges I, Gafumbegete E, Wagner T (1998) Subkutane Manifestationen eines zentrozytischen Non-Hodgkin-Lymphoms an Injektionsstellen eines Mistelpräparats. Dtsch Med Wochenschr 123:1001-1004
37. Hajto T, Hostanska K, Gabius H-J (1989) Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49:4803-4808
38. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius H-J (1990a) Increased secretion of tumor necrosis factor-α, interleukin-1, and interleukin-6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50:3322-3326
39. Hajto T, Hostanska K, Gabius H-J (1990b) Zytokine als Lektin-induzierte Mediatoren in der Misteltherapie. Therapeutikon 4:136-145
40. Hauser SP (1989) Misteltherapie bei Krebserkrankungen. Münch Med Wochenschr 131:609-613
41. Hauser SP (1993a) Mistel-Wunderkraut oder Medikament? Therapiewoche 43:76-81
42. Hauser SP (1993b) Unproven methods in cancer treatment. Curr Opin Oncol 5:646-654
43. Haustein K-O, Höffler D, Lasek R, Müller-Oerlinghausen B (1998) Außerhalb der wissenschaftlichen Medizin stehende Methoden der Arzneitherapie. Dt Ärztebl 95:A800-805
44. Heimpel H (1995) Letter to the editor. Tumordiagn Ther 16:205
45. Heiny B-M, Beuth J (1994) Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14:1339-1342
46. Herr HW, Laudone VP, Whitmore WF (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138:1363-1368
47. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF, Oettgen HF (1995) Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer: ten year follow-up of a prospective randomized trial. J Clin Oncol 13:1404-1408
48. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R (1995) A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14:295-304
49. Janssen O, Scheffler A, Kabelitz D (1993) In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung/Drug Res 43:1221-1227
50. Joller PW, Menrad JM, Schwarz T, Pfüller U, Parnham MJ, Weyhenmeyer R, Lentzen H (1996) Stimulation of cytokine production via a special standardized mistletoe preparation in an in vitro human skin bioassay. Arzneimittelforschung/Drug Res 46:649-653
51. Joshi SS, Komanduri KG, Gabius S, Gabius H-J (1991) Immunotherapeutic effects of purified mistletoe lectin on murine large cell lymphoma. In: Gabius H-J, Gabius S (eds) Lectins and cancer. Springer, Berlin Heidelberg New York, pp 207-216
52. Kaegi E (1998) Unconventional therapies for cancer. 3. Iscador. Can Med Assoc J 158:1157-1159
53. Kagawa S, Ogura K, Kurokawa K, Uyama K (1979) Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder cancer. J Urol 122:467-470
54. Kiene H (1989) Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Therapeutikon 3:347-353
55. Klebingat K-J (1998) Unkonventionelle - alternative Therapieverfahren in der palliativen urologischen Onkologie. Urologe 38:249-251
56. Kleijnen J, Knipschild P (1994) Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1:255-260
57. Klett CY, Anderer FA (1989) Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album. Arzneimittelforschung/Drug Res 39:1580-1585
58. Kunze E (1979) Development of urinary bladder cancer in the rat. Curr Top Pathol 67:145-232
59. Kunze E (1994) Preneoplastic and neoplastic lesions of the rat urinary bladder. In: Bannasch P, Gössner W (eds) Pathology of neoplasia and preneoplasia in rodents. Schattauer, Stuttgart New York, pp 108-124
60. Kunze E (1998) Hyperplasia, urinary bladder, rat. In: Jones TC, Mohr U, Hunt RD (eds) Urinary system. Monographs on pathology of laboratory animals. Springer, Berlin Heidelberg New York, pp 331-368
61. Kunze E, Chowaniec J (1990) Tumors of the urinary baldder. In: Turusov VS, Mohr U (eds) Pathology of tumours in laboratory animals. IARC Sci Publ 99:345-397
62. Kunze E, Schauer A (1977) Morphology, classification and histogenesis of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced carcinomas in the urinary bladder of rats. Z Krebsforsch 88:273-289
63. Kunze E, Schulz H, Ahrens H, Gabius H-J (1997) Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats. Exp Toxicol Pathol 49:167-180
64. Kunze E, Schulz H, Gabius H-J (1998) Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J Cancer Res Clin Oncol 124:73-87
65. Kuttan G, Menon LG, Kuttan R (1996) Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. Carcinogenesis 17:1107-1109
66. Lamm DL (1994) BCG therapy of papillary tumors: a review of worldwide phase III trails. In: Pagono F, Bassi P (eds) BCG immunotherapy in superficial bladder cancer. Cleup, Padova, pp 33-43
67. Lenartz D, Stoffel B, Menzel J, Beuth J (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16:3799-3802
68. Lenartz D, Andermahr J, Plum G, Menzel J, Beuth J (1998) Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma. Anticancer Res 18:1011-1014
69. Leong AS-Y, Wannakrairot JJ, Milios J (1990) Bacillus Guérin-treated superficial bladder cancer: correlation of morphology with immunophenotyping. J Pathol 162:35-41
70. Lu C, Rak JW, Kerbel RS (1997) Interleukin-6 in progression of human solid tumors: transitional changes in the regulation of cell growth, apoptosis and angiogenesis. Cancer J 10:256-261
71. Marx HH (1995) Wissenschaftliche Medizin oder alternative Heilmethoden - eine Grundsatzfrage. Med Klin 90:107-112
72. McGinnis LS (1991) Alternative therapies, 1990. An overview. Cancer 67:1788-1792
73. Mizutani Y, Nio Y, Yoshida O (1992) The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes. Cancer 69:2999-3007
74. Nseyo UO, Lamm DL (1996) Therapy of superficial bladder cancer. Semin Oncol 23:598-604
75. Oepen I (1994) Besondere Therapierichtungen. Dtsch Apoth Ztg 134:3008-3019
76. Okamoto M, Kawamata H, Kawai K, Oyasu R (1995) Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin-6. Cancer Res 55:4581-4585
77. Peuchmaur M, Benoit G, Viellefond A, Chevalier A, Lemaigre G, Martin ED, Jardin A (1989) Analysis of mucosal bladder leukocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 17:299-303
78. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636-1642
79. Ravoet C, De Gréve J, Vandewoude K, Kerger J, Sculier J-P, Lacor P, Stryckmans P, Piccart M (1994) Tumor stimulating effects of recombinant human interleukin-6. Lancet 344:1576-1577
80. Rohde D, Gastl G, Biesterfeld S, Plante M, Jakse G (1997) Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment with Nocardia rubra cell wall skeleton and bacille Calmette-Guérin. Urol Res 25:19-24
81. Sauer H (1996) Analyse des Immunstatus bei Patienten mit soliden Tumoren: klinische Relevanz? Münch Med Wochenschr 138:159
82. Sauer H (1998) Leserbrief. Onkologe 4:1180
83. Shapiro A, Kadmon D, Catalona WJ, Ratliff TL (1982) Immunotherapy of superficial bladder cancer. J Urol 128:891-894
84. Sogn JA (1998) Tumor immunology: the glass is half full. Immunity 9:757-763
85. Stein GM, Berg PA (1996) Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free extract on T-helper cells and monocytes in healthy individuals in vitro. Arzneimittelforschung/Drug Res 46:635-639
86. Stoll BA (1993) Can unorthodox cancer therapy improve quality-of-life? Ann Oncol 4:121-123
87. Stratmann F (1993) Charakteristika der anthroposophischen Medizin. In: Oepen I (ed) Unkonventionelle medizinische Verfahren. Fischer, Stuttgart, pp 68-95
88. Stumpf C, Büssing A (1997) Stimulation of antitumor immunity by intrapleural instillation of a Viscum album L. extract. Anticancer Drugs 8 [Suppl 1]:S23-26
89. Tsujihashi H, Matsula H, Mejima S, Akiyama T, Kurita T (1988) Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol 140:890-894
90. Tsujihashi H, Matsuda H, Mejima S, Akiyama T, Kurita T (1989) Immunoresponse of tissue infiltrating lymphocytes in bladder tumors. J Urol 141:1467-1470
91. Zarkovic N, Zarkovic K, Grainca S, Kissel D, Jurin M (1997) The Viscum album preparation Isorel inhibits the growth of melanoma B16-F10 by influencing the tumour-host relationship. Anticancer Drugs 8 [Suppl 1]:S17-S22